Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review Article

Relationship of COVID-19 with pregnancy

Umme Salma

Department of Obstetrics & Gynecology, Jouf University, Sakaka, Saudi Arabia

A R T I C L E   I N F O

Article history:
Accepted 19 January 2020

Keywords:
COVID-19
Pregnant women
Neonate

A B S T R A C T

COVID-19 a pandemic disease caused by the SARS-CoV2 virus, which has been emerged in Wuhan city China from early December 2019 which subsequently spreading globally. As a consequence of the physiological adaptive changes and immunosuppressive condition during pregnancy are more susceptible to respiratory tract infection and pneumonia that perhaps makes them more at risk to COVID-19. There is scarce information available on COVID-19 pregnancy and no reliable evidence for vertical transmission. It is a concern that newborns are at risk from postpartum contamination. Meanwhile, there was no vaccine and specific therapeutic drugs for COVID19. The Multidisciplinary team will manage by close supervision, isolated negative pressure room, and routinely fetal monitoring. The timing and mode of delivery depend on the critical condition of the mother and fetal. The newborns need a 14 days period of precautionary isolation. In the present study, addressed the most recent data on 149 pregnant women and 96 newborns with typical symptoms and planning of management which response to COVID-19 that will help for frontline doctor to the management of COVID-19 associated pregnancy and newborns baby. Repeated testing, contact tracing and self-isolation will assist to control the spread of SARS-CoV2 infection and COVID-19 disease until specific vaccine and pharmaceuticals drugs of COVID-19 are available.

© 2021 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0).
patients manifest upper and lower respiratory symptoms. The receptor-binding domain of SARS-CoV-2 shown to be a mutated version of its generally intimately associated virus according to their genomic sequence [20]. Based on pandemic laboratory trials the pathophysiological mechanism of SARS-CoV-2 are still unidentified, while the similarity of genomic sequence SARS-CoV may provide clarification for the inflammatory reaction that appears as pneumonia [13]. The structure of COVID-19 represents in (Fig. 1).

Transmission

The animal source of SARS-CoV2 and genomic strain closely related to bats [21]. The first COVID-19 patient-related in Wuhan at the seafood wholesale market, and perhaps spread from animal to human, after while many cases existing coronavirus but this theory was failure to support. There was reliable evidence for transmission of COVID-19 from human-to-human [22,23]. The respiratory droplets and contact spreading is the main pathway for transmission. Few data exist coronavirus may cause complications mainly in the third trimester of pregnancy but may not support the vertical transmission from mother to fetus, while the newborns affected by contamination mother (Fig. 2).

Clinical characteristic

The limited data are available for COVID- 19 infected pregnant women. Several studies have appeared in a document the common symptoms are fever, cough, lymphopenia, chest pain and a small number of patients develop diarrhea and shortness of breath [24,26–28]. The pattern of clinical characteristics of COVID-19 pregnant women has like non-pregnant with COVID-19. The expected symptoms developed 3–6 days after exposure. From the 41 hospitalized cases presented with fever, cough, fatigue approximately number of 30, 24, and 7, while fewer symptoms were loss of appetite 3 and diarrhea 1 respectively [27]. Total of 149 patients with COVID-19 included this study with symptoms such as fever 149, cough 140, fatigue 48, and malaise 29 pregnant women with complications mainly presented in the mid and late gestational weeks [12,24,26,30–36]. However, it is of note that the outbreaks of COVID-19 virus in early pregnancy are unidentified [14]. The physiology alternation of pulmonary function during pregnancy may risk for COVID-19 that implement the susceptibility and severity of pneumonia [26,37,38]. Clinical characteristic represented in (Table 1).

Analysis of investigated reports

The laboratory findings normal or decrease white blood cells, low lymphocyte, and increased C-reactive protein. Many women have experienced mild thrombocytopenia, raise creatine phosphokinase, and liver enzymes in addition to high alanine aminotransferase (ALT) and aspartate aminotransferase (AST) [26]. Routinely analysis of urine and stool has a facility to detect the condition of the virus and shedding of the virus. Currently, the real-time reverse transcription-polymerase chain reaction (RT-PCR) assay used for confirmation of SARS-CoV-2 from throat swab who suspected COVID-19 [41]. United states have build 84 public health laboratories for testing of COVID-19 the specific primers of this test for SARS-CoV-2 to target their envelope, RNA-dependent RNA polymerase (RdRp), and nucleocapsid genes [42]. These detected which RdRp assay has capable the maximum analytical sensitivity. However, using the RT-PCR method to amplification of DNA and viral load in COVID-19 which may likely theoretically explanation. Regarding detecting of COVID-19 from a specimen of the lower respiratory tract has more diagnostic value comparatively upper respiratory tract [43], WHO preferred a high significance for the detection of COVID-19 from a specimen of the lower respiratory tract such as sputum, endotracheal aspirate, or bronchoalveolar lavage. A specimen of the upper respiratory tract required when asymptomatic of the lower respiratory tract infection or situation demand. Chest radiograph or CT scan provides essential knowledge for the clinical state of COVID-19 in pregnant [43–46].

Management

The tertiary hospitals were better for the isolation with the initial management of COVID-19 infected pregnant women. The health care should be concerns about isolates negative-pressure room for confirm case, and suspected cases only need isolates. The hospitals should exist negative-pressure room in ICU and NICU [47]. All physician and medical staff should be self-protection by PPE (such as gown, N95 masks, goggles, and gloves) during dealing with patients [48]. There is no confirmed evidence for vaccine and
specific antiviral drugs against COVID-19. The principle treatment for severe COVID-19 infection has symptomatic and oxygen therapy. In addition to mechanical ventilation requires if respiratory failure refractory to oxygen therapy, besides, the management of septic shock by hemodynamic support. Although, no approved antiviral for COVID-19, but may propose several approaches like lopinavir or ritonavir (400/100 mg every 12 h), chloroquine (500 mg every 12 h), and hydroxychloroquine (200 mg every 12 h). Besides, Alpha-interferon (e.g., 5 million units by aerosol inhalation twice per day) has used. However, COVID-19 with pneumonia treated by antibiotics [39]. It is also essential to apply supportive therapies such as the fluid infusion, adequate rest and proper nutritional diet. The management protocol represents a diagram in (Fig. 3).

**Fetal monitoring**

It needs to regular monitoring of fetal heart rate by stethoscope or Doppler with compatible and dependable on gestational weeks, while ultrasound considered a stander method to determine fetal deformity, any intrauterine complication, and fetal death. Close supervision might help to make a decision, to continue a pregnancy or emergency termination and delivery.

**During pregnancy**

The antiviral drugs with the regimen of Lopinavir or Ritonavir are comparatively safe during pregnancy [49,50]. The WHO proposed, before the selection of this drug for COVID-19 infection should be knowledge of their advantage and disadvantage. While remdesivir and chloroquine drugs have well, predictable to inhibit the SARS-COV-2 virus in vitro, based on this information these drugs may potentially effect on COVID-19 [51]. Above this drug started a clinical trial in China (ClinicalTrials.gov number NCT04252664 and NCT04257656) and United States (Clinical Trials. gov number NCT04280705). Recently reported Chloroquine drug may discontinue the coronavirus infection by excessive endosomal pH requires for cell fusion and disturbance the glycosylation of cellular receptors of SARS-CoV [51]. Chloroquine can safely pre-scribe whole trimesters of pregnancy and no interfere of perinatal outcomes [52]. Therefore, the recommended dose should increase maximum 500 mg twice daily in cases of COVID-19 infection. While the reported increased dose of chloroquine may cause systolic hypotension that aggravates the hemodynamic changes from supine aortocaval compression by a gravid uterus [53]. WHO declares, there was no benefit to routinely use of systemic corticosteroids because of the delay clearance of virus [16,54,55]. Currently, the U.S. National Institutes of Health (NIH) will trial mRNA-1273 vaccines (ClinicalTrials.gov number NCT 04283461) on non-pregnant women but it is uncertain to pregnant women.

**Delivery approach**

There is no evidence for termination of pregnancy due to COVID-19 infection. Adequate care, proper treatment, and follow-up may continue to term pregnancy. The critical condition of patients will discontinue the pregnancy because of the endangering mother and fetus by emergency delivery on the consent of the patient’s family. The clinicians should be self-protection and know the severity of risk during dealing with labor patients. The time and mode of delivery are depending on the status of the mother and fetal [56]. Currently, there was no reliable reported for vertical transmission and contraindication of vaginal delivery of COVID-19 patients [12,53]. The vaginal delivery preferred when labor will progress actively with the spontaneous onset and operative delivery concern to shortening the second stage of labor [57]. The present study review thirty-three vaginal deliveries without any difficulty, therefore it indicates vaginal delivery is possible for COVID-19 mother. Conversely, for cesarean delivery, the operative room should be confirmed with negative pressure and well ventilation. The surgeon should self-protect with (PPE) during the surgery procedure of COVID-19 patients. Besides, the cesarean section
**Table 1**
Clinical aspects and management of COVID-19 infected pregnant women.

| Authors                  | N - case | Age     | Weeks of gestation | C/F                        | Progression | Treatment                                                                 | Delivered | Neonatal outcomes | Neonatal complications |
|--------------------------|----------|---------|--------------------|----------------------------|-------------|---------------------------------------------------------------------------|-----------|--------------------|------------------------|
| Chen et al. [11]         | 9        | 26–40   | 36–39              | Fever, malaise, cough      | Pneumonia   | Antiviral therapy                                                       | CS        | Normal            | No                     |
| Nan yu et al. [24]       | 7        | 29–34   | 37–41              | Fever, cough, fatigue      | Pneumonia   | Antibiotic therapy, Oseltamivir (75 mg 12 h, orally), Ganciclovir (0.25 g every 12 h, intravenously), interferon (40 μg daily) | CS        | 1 had positive to SARS-CoV-2 | No                     |
| Huang hua leu et al. [27]| 41       | 22–42   | 22–40              | Fever, cough, fatigue      | Pneumonia   | Antiviral therapy                                                       | Not reported | Normal            | 3 had cough, fever, 1 had fatigue | No                     |
| Huangping Zhu et al. [29]| 9        | 25–34   | 31–39              | Fever, cough, diarrhea     | Pneumonia   | Oseltamivir, nebulized inhaled interferon                                | 2-VD      | CS                | Normal                 | No                     |
| Dehan Liu et al. [36]    | 15       | 23–40   | 12–38              | Fever, cough, sore throat, myalgia | Pneumonia   | Antiviral therapy                                                       | 1-VD      | 10-CS             | 4-cont. pregnancy       | Normal                 | No                     |
| Na Li et al. [37]        | 16       | 26–37   | 29–40              | Fever, cough, sore throat, dyspnea, Fever, cough | Pneumonia     | Antiviral therapy                                                       | 2-VD      | 14 – CS           | Normal                 | No                     |
| Xiaotong Wang et al. [48]| 1        | 28      | 30                 | Fetal distress             | Fetal distress | Antiviral therapy                                                       | CS        | Normal            | No                     |
| Weiyong LIU et al. [56]  | 3        | 30–34   | 38–40              | Fever, cough               | pneumonia    | Atomized inhalation of interferon (40 μg, bid), Ganciclovir (0.25g, IV), Oseltamivir, Azithromycin, hydroxychloroquine | 1-VD      | 2-CS              | Normal                 | 1 had slightly decreased responsiveness and muscle tone | No                     |
| E. Kalafat et al. [57]   | 1        | 32      | 35 + 3             | Cough, dyspnea             | pneumonia    | Oseltamivir, Azithromycin, hydroxychloroquine                           | CS        | Normal            | No                     |
| Siyu Chen et al. [59]    | 5        | 25–31   | 38–41              | Cough, malaise, Dyspnea, myalgia, Dyspnea, fever, cough | Preeclampsia | GDM                                                                        | 3-VD      | 2-CS              | Normal                 | No                     |
| Fabio Parazzin et al. [60]| 42      | 21–44   | 34–37              |                                         | pneumonia    | Not reported                                                             | 24-VD     | 18-CS             | Total 3 had Positivity to SARS-Cov-2, among 1 had missing information | 1 had gastrointestinal and respiratory symptoms | No                     |

Abbreviations: CS – cesarean section, VD – vaginal delivery, GDM – Gestational diabetes mellitus.
preferred in two cases of COVID-19 pregnant women due to the failure of induction and arrest of the descendent part [26]. Current reported on eleven COVID-19 patients (12–38 gestational week), among ten patients delivered by cesarean section and one patient by vaginal delivery with no complication or death of newborns. Similar reported to seven patients had CS with good neonatal outcomes except one who had positive SARS-CoV-2 (Table 1) [25,37]. Several cases of COVID-19 with pneumonia preferred either emergency or scheduled CS [29,38,58–62].

Based on evidence from the review studies reveals that the expert recommendations for the management of COVID-19 pregnant women. A total of 149 pregnant women with COVID-19 have been reported the approaches of delivery, among 77 and 33 pregnant women by cesarean and vaginal delivery respectively. Moreover, the prescribed drug as the only antibiotic had 15, antibiotic with oral antiviral oseltamivir has prescribed 75 mg, intravenous ganciclovir 0.25 g every 12 h had 16, antibiotic with lopinavir 400 mg, ritonavir 100 mg every 8 h had 1, and arbidol 200 mg had 8 COVID-19 pregnant women. Conversely remaining 109 pregnant women prescribed antibiotics with or without antiviral drugs but the name of antiviral drugs was not reported. Most of these cases the expert suggested antibiotic and antiviral drugs because of benefited effects found to use of antibiotic as prophylaxis such as azithromycin, cefoxazole, and cephalosporin before delivery and some of the cases continued after delivery. The antiviral favipiravir drug was also used but the dosage was not mentioned. Above discussion, it was clearly understood that antibiotic along with oseltamivir and ganciclovir were vastly used may provide better outcomes. As well the multidisciplinary team recommended to start of combined antibiotic and antiviral drugs after diagnosis of cases and preferred cesarean delivery that may better improve the condition and avoided the complications of both mother and fetus. Though there was no contraindication of vaginal delivery but limited data available. Perhaps the widely used of this management has may prognosis of maternal and fetal outcomes.

**Neonatal outcomes**

The Present study reviews a total one-hundred forty-nine pregnant women with COVID-19 positive who gave delivery ninety-six newborns among 1 had died due to DIC and multiple organ failure. The Apgar scores of all 95 infants had ≥7 at 1 min and ≥9 at 5 min respectively. The collected of nasopharyngeal swab from all 95 infants for COVID-19 had tested by SARS-Cov2-19 PCR. Four infants had shown COVID-19 positive among 1 had missing information, while 91 had shown COVID-19 negative. To minimize the risk of contact transmission the neonate was isolated whereas other family member and as well as nurses were taken care of them. As well, 10 neonates had breastfeeding with mother using surgical masks. The one COVID-19 positive neonate had admitted to the specialized design of children’s hospital and two neonates admitted into the NICU, after two weeks one infant was discharged home by two consecutive negative nucleic acid tests, while two neonates were improved after ventilation but insufficient information about discharge.

**Neonatal complications**

Total six neonate were addressed of some complication after delivery, such as three neonates had fever, cough, 1 had fatigue, 1 had gastrointestinal and respiratory symptoms and 1 had slightly decreased responsiveness and muscle tone respectively.

**Care of the newborn**

To our knowledge, there was no reliable evidence for SARS-CoV-2 viral detected in conception product, fetus, amniotic fluids, placenta and breastfeeding of COVID-19 pregnant women [14]. Recent studies reported on two neonates have identified the COVID-19 infection after 36 h and 17 days of delivery due to postpartum contamination [63]. It is advisable to early umbilical cord
clamping and isolates newborns at least 14 days to reduce the viral transmission. Two COVID-19 infected mothers had breathed without the use of surgical masks, the one newborn was infected, and one has suspected on the first and third day [62]. Newborns with suspected SARS-CoV2 need to immediately isolation with a chest CT scan, swab specimens, and nucleic acid test (NAT) [30]. The COVID-19 infected mother suffered hypoxemia that adverse effects on fetal such as birth asphyxia and premature birth. The obstetricians should concern with neonatologist during preparing for resuscitation of a neonate in the delivery room to facilitate the prognosis of the neonate. To ensure the health support to guarantee all facility to suspected newborns.

Conclusion

Pregnant women infected with COVID-19 need to more intensive attention. Currently, there is limited data on COVID-19 with pregnancy and found mostly during late pregnancy which is risks for mother and fetus. During late pregnancy of COVID-19 infected mother may risk of adverse obstetrical outcomes. A multi-disciplinary team contact should be adopted for dealing with these patients as it allows effectively sharing knowledge and expertise as well as responsibility. However, repeated testing, contact tracing, and self-isolation may control the spread of SARS-CoV2 and COVID-19 infection until specific treatment either by vaccine or drugs are available.

Declaration of competing interest

None.

References

[1] Sahu Kamal Kant, Lal Amos, Mishra Ajay Kumar. COVID-19 and pregnancy: a plea for transparent reporting of all cases. Acta Obstet Gynecol Scand 2020;99:1–13.
[2] Zhi N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China. New Engl J Med 2020;393:127–33.
[3] World Health Organization (Who). Novel coronavirus-China. 28 February. https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/ 2020.
[4] Chen N, Zhong M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.
[5] Chen Y, Liu G, Guo D. Coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 2020;92:418–23.
[6] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. J Am Med Assoc 2020;323(13):1239–42.
[7] Wang Sforl, Chow K, Li, Bao F, Ng X, Tak K, Shek C, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol 2004;191(1):292–7.
[8] Alfaraj SH, Al-Tawfiq JA, Memish ZA. Middle East respiratory syndrome coronavirus (MERS CoV) infection during pregnancy: report of two cases and review of the literature. J Microbiol Immunol Infect 2019;52:501–5.
[9] Zaki AH, Boheemen Sander van, Besterbroe Theo M, Albert Osterhaus, Ron AM. Isolation of a novel coronavirus from a man with pneumonia in the Netherlands. Lancet 2003;361:1777–8.
[10] World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). 2020. [11] Chen Hujun, Guo Juanjuan, Wang Chen, Fan Luo, Yu Xue chen, Zhang Wei, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020;395(10226):809–15.
[12] Lu Roujian, Zhao Xiang, Li Juan, Niu Peihua, Yang Bo, Wu Honglong, et al. Genomic characteristic on and epidemiology of 2019 novel coronavirus infections for virus origins and receptor binding. Lancet 2020;395(10224):565–74.
[13] Qiao J, What are the risks of COVID-19 infection in pregnant women? Lancet 2020;395:760–2.
[14] Lam Chui Miu, Wong Shell Fau, Leung Tse Nng, Chow Kam Ming, Yu Wai Cho, Wong Tin Yau, et al. A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory infection. BJOG 2004;111:771–4.
[15] World Health Organization (Who). Clinical management of severe acute respiratory infection when Novel coronavirus (2019-nCoV) infection is suspected: interim Guidance. Feb 28, https://www.who.int/publications-detail/coronavirus-novel-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected-2020.
[16] Centers for Disease Control and Prevention (Cdc). Interim considerations for isolation of patients with 2019 novel coronavirus disease 2019 (COVID-19) in inpatient obstetric healthcare settings. Feb 28, https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control.html.
[17] Fan Yi, Zhao Kai, Zheng-Li Shi, Zhou Peng. Bat coronavirus in China. Viruses 2019;11(2):101–14.
[18] Kisekew Thomas G, Dean Erdman, Goldsmith Cynthia S, Zaki Sherif R, Peret Teresa, Shannon Emery, et al. A novel coronavirus virus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953–66.
[19] Andiyas Kristian, Rambaut Andrew, Lipkin Wain, Holmes Edward, Garry Robert F. The proximal origin of SARS-CoV-2. Nat Med 2020;26:450–5.
[20] Shulla A, Heald-Sargent T, Subramanmya G, Zhao J, Perlman S, Gallaghe T. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol 2011;85:873–92.
[21] Graham Carlos W, Charles S, Cao Dela Cruz Bin, Pasnick Susan, Jamil Shazia, Sockrider Marianna, et al. Novel wuhan (2019-nCoV) coronavirus. Am J Respir Crit Care Med 2020;191:2–8.
[22] Wan Yuyun, Shan Jiang, Graham Rachel, Baric Ralph S, Li Fang. Receptor recognition by novel coronavirus from Wuhan: analysis based on decade-long structural studies of SARS. J Virol 2020;94(7):e00127–20.
[23] Chen Lian, Qin Li, Zheng Danni, Jiang Hail, Yuan Wei, Zhou Li, et al. Clinical characteristics of pregnant women with COVID-19 in Wuhan, China. The New England Journal of Medicine 2020;30:1–3.
[24] Nan Yu, Li Wei, Kang Qingxiong, Xiong Zhi, Wang Shaozhui, Lin Xingqiang. Clinical features and obstetric and neonatal outcomes of pregnant women with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. Lancet Infect Dis 2020;20(5):599–604.
[25] Jiao Juan. Under the epidemic situation of COVID-19, should special attention be given to pregnant women be given. J Med Virol 2020;92:1–2.
[26] Huang Chaolin, Wang Yeming, Li Xingwang, Ren Lili, Zhao Jianping, Hu Yi, et al. Clinical features of patients infected with novel 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
[27] Liu Huanhuan, Liu Fang, Li Jinping, Zhong Tianting, Wang Dengbin, Lin Weishun. Clinical and CT imaging features of the COVID-19 pneumonia: focus on pregnant women and children. J Infect 2020;80:e7–13.
[28] Jin Yuefeng, Yang Hayan, Ji Wangjun, Wu Wendong. Epidemiology, pathogenesis, and control of COVID-19. Viruses 2020;12(372):1–10.
[29] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. J Am Med Assoc 2020;323(13):1239–42.
[30] Wright DA, Graham AL. Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections. Viruses 2020;12:194.
[31] To KE, Lo AW. Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2). J Pathol 2004;203:740–3.
[32] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. J Am Med Assoc 2020;323(13):1239–42.
[33] Tong Zhen-Dong, Tang An, Li Ke-Feng, Peng Li, Wang Hong-Ling, Yin Jing-Ping, et al. Potential transmission characteristics of SARS-CoV-2, Zhejiang province China. 2020. Emerg Infect Dis 2020;26(5):1052–4.
[34] Bai Y, Yao L, Wei T, Fei-Tiao, Dong-YianJin, LijuanChen, et al. Presumed asymptomatic carrier transmission of COVID-19. J Am Med Assoc 2020;323(14):1406–7.
[35] Kampf G, Todt D, Pflander S, Steinnmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020;104:246–51.
[36] Liu Dehan, Lin Li, Wu Xin, Zheng Dandan, Wang Jiazhang, Yang Lian, et al. Pregnancy and perinatal outcomes of women with coronavirus disease (COVID-19) pneumonia: a preliminary analysis. AJR 2020;215:1–6.
[37] Li Na, Han Leifi, Peng Li, Wang Hong-long, et al. Potential presence of vertical transmission of novel coronaviruses from mother to neonate: case control study. Clin Infect Dis 2020;71(16):2035–41.http://doi.org/10.1093/cid/ciaa352. caa.
[38] Diagnosis and treatment guideline for COVID-19 infection (trial version 6) [in Chinese].National Health Commission of the People’s Republic of China website. March 18, http://www.nhc.gov.cn; 2020.
[39] Lauer SA, Grantz KH, BiQ Jones FK, Zheng Q. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported con-}
Poon LC, Yang H, Lee JCS, Copel JP, Leung TY, Zhang Y, et al. SUOG Interim Guidance on 2019 novel corona virus infection during pregnancy and puerperium: information for healthcare professionals. Ultrasound Obstet Gynecol 2020;55:700–8. https://doi.org/10.1002/uog.22013.

Yang Li, Liming Xia. Corona virus disease 2019 (COVID-19): role of chest CT in diagnosis and management. AJR 2020;214:1280–6.

Zhao Wei, Zhong Zhong, Xie Xingzhi, Yu Qizhi. Relation between chest CT findings and clinical conditions of corona virus disease (COVID-19) pneumonia: a multicenter study. AJR 2020;214:1072–7.

Tao Ai, Yang Zhenlu, Hou Hongyan, Zhan Chenao, Chen Chong, Lv Wenzhi, et al. Correlation of chest CT and RT-PCR testing in corona virus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology 2020;26:200642. https://doi.org/10.1148/radiol.2020200642.

The Lancet. Emerging understandings of 2019-nCoV. Lancet 2020;395(10221):311.

Maxwell C, McGeer A, Tai KFY. Management guidelines for obstetric patients and neonates born to mothers with suspected or probable severe acute respiratory syndrome (SARS). J Obstet Gynaecol Can 2017;39(8):e130–7.

Qi H, Chen D, Feng L, Zou L, Li J. Obstetric considerations on delivery issues for pregnant women with COVID-19 infection. Chin J Obstet Gynecol 2020;55(2):E001–E001.

Yang H, Wang C, Poon LC. Novel corona virus infection and pregnancy. Ultrasound Obstet Gynecol 2020;55:435–7.

Liu Weiyong, Wang Qianli, Zhang Qi, Chen Ling, Chen Junbo, Zhang Bo, et al. Corona virus disease 2019 (COVID-19) during pregnancy: a case series. Preprints 2020;1-202003373.

Kalafat E, Yaparak E, Cinar G, Varli B, Ozisik S, Uzun C, et al. Lung ultrasound and computed tomographic findings in pregnant woman with COVID-19. Ultrasound Obstet Gynecol 2020;55:835–7. https://doi.org/10.1002/uog.22014.

Chen Siyu, Liao E, Cao Dongmei, Gao Ying, Sun Guoqing. YongShao. Clinical analysis of pregnant women with 2019 novel corona virus pneumonia: J Med Virol 2020;1–6.

Parazzini Fabio, Ferrazzi Enrico, Frigerio Luigi. Mode of delivery and clinical findings in COVID-19 infected pregnant women in northern Italy powered by editorial manager and ProduXion manager from aries systems corporation 2020.

Working group for the prevention and control of neonatal 2019-nCoV infection in the perinatal period of the editorial committee of Chinese journal of contemporary pediatrics. Perinatal and neonatal management plan for prevention and control of 2019 novel corona virus infection (1st Edition). Chinese Journal of Contemporary Pediatrics 2020;22:87–90.

World Health Organization (Who). Novel coronavirus technical guidance: patient management. February 20, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/patient-management; 2020.